SGLT2is may delay ESKD by 15 years. A typical patient included in CREDENCE would lose 4.6 ml/min per year of eGFR if treated with RAASi only, reaching ESKD in 10 years. However, if canagliflozin is added to his treatment, he would only lose 1.85 ml/min per year of eGFR, delaying ESKD by 15 years. RAASi, renin-angiotensin-aldosterone system inhibitors; SGLT2i, sodium-glucose cotransporter 2 inhibitor.